Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor.
Jaypirca, a highly selective kinase inhibitor, which uses a novel binding mechanism. Jaypirca has the ability to restore BTK inhibition in MCL in patients who have earlier treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) and extend the benefit of targeting the BTK pathway. Jaypirca will beocme the new treatment option and brings new hope for people with relapsed or refractory MCL.
Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300-fold selective for BTK compared to 98% of other kinases tested in preclinical studies), non-covalent (reversible) enzyme. Jaypirca is an oral prescription drug approved as 100 mg or 50 mg tablets taken once daily. 200 mg with or without food until disease progression or toxicity is unacceptable.
U.S. Food and Drug Administration (FDA) approves Jaypirca™ for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
